In our study, there were significant differences in bone metastasis, NSE, LDH, MTV and TLG between patients with progression and those without; age, sex, MYCN amplification, GD2 expression, tumor location, lymph node metastasis, other distant metastasis, bone marrow involvement, risk stratification and SUVmax showed no significant differences between the two groups (Table 1). The gene discussed is ENO2; the disease is metastasis.